Urolon Company
Rethinking stress incontinence treatment with Urolon®, an innovative bioresorbable urethral injectable as a first choice, minimally invasive treatment after pelvic floor muscle therapy. Urolon® bridges the gap between conservative and surgical interventions. CE certified since 2018, available in 12 countries.
Industry:
Pelvic & Uterine Healthcare
Headquarters:
Utrecht, The Netherlands
Founded Date:
03-01-2014
Employees Number:
1-10
Funding Status:
Self-funded
Total Funding:
$6,000,000
Estimated Revenue:
Less than $1M
Register and Claim Ownership